Concert Pharmaceuticals, Inc. ( CNCE ) saw a big move last session, as the company's shares fell by over 5% on the day. The move came on pretty good volume too with far more shares changing hands than in a normal session. This continues the recent downtrend for CNCE, as the stock is now down over 4% in the past one-month time frame.
The medical company has seen a flat record when it comes to current year estimate revisions over the past few weeks (0 increases, 0 decreases), and the consensus for earnings hasn't been in a trend either. This recent price action is discouraging, so make sure to keep a close watch on this firm in the near future, and especially on earnings estimates following the recent slump.
CNCE currently has a Zacks Rank #4 (Sell) while its Earnings ESP is 0.00%.
Investors interested in the medical industry may consider better-ranked stock like Portola Pharmaceuticals, Inc. ( PTLA ), which carries a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.